Optical properties of irregular interstellar grains

In order to study the interaction of light with interstellar grains, the authors represent an irregular particle by a network of interacting dipoles whose polarizability is determined in a first approach by the Clausius-Mossoti relationship. Typically, 10,000 dipoles are considered. In the case of spherical particles, the results from Mie theory are fully recovered. The main interest of this method is to study with good accuracy the implications of surface roughness and/or inhomogeneities on optical properties in the infrared spectral range, particularly of the silicate emission features

Evolution of the Dust Coma in Comet 67P/Churyumov-Gerasimenko Before 2009 Perihelion

Comet 67P/Churyumov-Gerasimenko is the main target of ESA's Rosetta mission and will be encountered in May 2014. As the spacecraft shall be in orbit the comet nucleus before and after release of the lander {\it Philae}, it is necessary necessary to know the conditions in the coma. Study the dust environment, including the dust production rate and its variations along its preperihelion orbit. The comet was observed during its approach to the Sun on four epochs between early-June 2008 and mid-January 2009, over a large range of heliocentric distances that will be covered by the mission in 2014. An anomalous enhancement of the coma dust density was measured towards the comet nucleus. The scalelength of this enhancement increased with decreasing heliocentric distance of the comet. This is interpreted as a result of an unusually slow expansion of the dust coma. Assuming a spherical symmetric coma, the average amount of dust as well as its ejection velocity have been derived. The latter increases exponentially with decreasing heliocentric distance (\rh), ranging from about 1 m/s at 3 AU to about 25-35 m/s at 1.4 AU. Based on these results we describe the dust environment at those nucleocentric distances at which the spacecraft will presumably be in orbit. Astronomy and Astrophysics, in pressComment: 5 pages, 4 figure

Millimetre continuum observations of comet C/2009 P1 (Garradd)

Little is known about the physical properties of the nuclei of Oort cloud comets. Measuring the thermal emission of a nucleus is one of the few means for deriving its size and constraining some of its thermal properties. We attempted to measure the nucleus size of the Oort cloud comet C/2009 P1 (Garradd). We used the Plateau de Bure Interferometer to measure the millimetric thermal emission of this comet at 157 GHz (1.9 mm) and 266 GHz (1.1 mm). Whereas the observations at 266 GHz were not usable due to bad atmospheric conditions, we derived a 3-sigma upper limit on the comet continuum emission of 0.41 mJy at 157 GHz. Using a thermal model for a spherical nucleus with standard thermal parameters, we found an upper limit of 5.6 km for the radius. The dust contribution to our signal is estimated to be negligible. Given the water production rates measured for this comet and our upper limit, we estimated that Garradd was very active, with an active fraction of its nucleus larger than 50%.Comment: Accepted for publication in Astronomy & Astrophysics. 5 pages, 2 figure

Polarimetry and photometry of the peculiar main-belt object 7968 = 133P/Elst-Pizarro

133P/Elst-Pizarro is an object that has been described as either an active asteroid or a cometary object in the main asteroid belt. Here we present a photometric and polarimetric study of this object in an attempt to infer additional information about its origin. With the FORS1 instrument of the ESO VLT, we have performed during the 2007 apparition of 133P/Elst-Pizarro quasi-simultaneous photometry and polarimetry of its nucleus at nine epochs in the phase angle range 0 - 20 deg. For each observing epoch, we also combined all available frames to obtain a deep image of the object, to seek signatures of weak cometary activity. Polarimetric data were analysed by means of a novel physical interference modelling. The object brightness was found to be highly variable over timescales <1h, a result fully consistent with previous studies. Using the albedo-polarization relationships for asteroids and our photometric results, we found for our target an albedo of about 0.06-0.07 and a mean radius of about 1.6 km. Throughout the observing epochs, our deep imaging of the comet detects a tail and an anti-tail. Their temporal variations are consistent with an activity profile starting around mid May 2007 of minimum duration of four months. Our images show marginal evidence of a coma around the nucleus. The overall light scattering behaviour (photometry and polarimetry) resembles most closely that of F-type asteroids.Comment: Accepted by Astronomy and Astrophysic

Normal subgroups in the Cremona group (long version)

Let k be an algebraically closed field. We show that the Cremona group of all birational transformations of the projective plane P^2 over k is not a simple group. The strategy makes use of hyperbolic geometry, geometric group theory, and algebraic geometry to produce elements in the Cremona group that generate non trivial normal subgroups.Comment: With an appendix by Yves de Cornulier. Numerous but minors corrections were made, regarding proofs, references and terminology. This long version contains detailled proofs of several technical lemmas about hyperbolic space

Intravenous ibandronate in men with osteoporosis: An open pilot study over 2 years

In the treatment of osteoporosis, the tolerance of oral bisphosphonates is often low. The high potency of ibandronate allows iv bolus injections that can be repeated every 2 to 3 months. However, the best dose and time interval of the treatment with iv ibandronate is still debated. Efficacy of 2-mg ibandronate injected every 3 months was tested in men with osteoporosis over 2 yr, in a prospective, open study. Fourteen men with primary osteoporosis, mean age 57±12 yr (range: 40-73), received 2-mg ibandronate iv every 3 months over 2 yr. All got 1 g/day calcium and 880 UI/day vitamin D for 2 yr. Bone mineral density (BMD) increased after 2 yr by 6.7±1.5% (mean change±SEM) at lumbar spine (p<0.001), by 3.2±08% at trochanter (p<0.001) and by 1.4±1.1% at femoral neck (ns). Serum ß-crosslaps and osteocalcin decreased significantly by 30-45 and 30%, respectively, during the 2 yr of treatment. Serum calcium increased from the lower to the middle tertile of the normal range during the 2 yr of the study. The observed decrease of bone remodelling and the increase of BMD are of the same magnitude as those described with oral bisphosphonates. The increase of plasma calcium confirms the positive effect of the supplementation with calcium and vitamin D. These results suggest that 3 months are a good interval between two doses of iv ibandronate, when 2 mg are give

Identification of Pro-MMP-7 as a Serum Marker for Renal Cell Carcinoma by Use of Proteomic Analysis

International audienceBACKGROUND: No validated renal cell carcinoma (RCC) marker is known for detection of asymptomatic disease in selected populations or for prognostic purposes or treatment monitoring. We identified immunogenic proteins as tumor markers for RCC by combining conventional proteome analysis with serological screening, and we investigated the diagnostic clinical value of such markers in serum. METHODS: We studied the immunogenic protein expression profile of CAL 54, a human RCC cell line, by 2-dimensional electrophoresis combined with immunoblotting using sera from healthy donors compared with RCC patients. We developed a homogeneous, fluorescent, dual-monoclonal immunoassay for metalloproteinase 7 (MMP-7) and used it to measure MMP-7 in sera from 30 healthy donors, 30 RCC patients, and 40 control patients. RESULTS: Pro-MMP-7 (29 kDa; pI 7.7) in the CAL 54 cell line secretome was an immunogenic protein reactive with RCC patient sera but not with control sera. The concentrations of pro-MMP-7 were increased (P <0.0001) in sera of RCC patients (median 7.56 microg/L; range 3.12-30.5 microg/L) compared with healthy controls (median 2.13 microg/L; range 0.17-3.5 microg/L). Serum pro-MMP-7 had a sensitivity of 93% (95% CI 78%-99%) at a specificity of 75% (59%-87%) for RCC in the samples tested. CONCLUSION: Proteomics technology combined with serology led to the identification of serum pro-MMP-7 as a marker of RCC and represents a powerful tool in searching for candidate proteins as biomarkers

Full-Course Oral Levofloxacin for Treatment of Hospitalized Patients with Community-Acquired Pneumonia

Most guidelines for the management of hospitalized patients with community-acquired pneumonia (CAP) recommend commencing therapy with intravenous antibiotics, primarily because of concern about absorption of oral antibiotics in acutely ill patients. However, patients who respond are rapidly switched to oral therapy, which has been shown to reduce costs and to shorten the length of stay. The aim of the present study was to determine whether a full course of oral antibiotics is as efficacious and as safe as intravenous-to-oral sequential antibiotic therapy for the treatment of hospitalized, non-ICU patients with CAP. In an open-labelled, controlled study, 129 hospitalized patients with CAP were randomly assigned in a 2:1 ratio to receive either a full course of oral levofloxacin (500mg q12h) or an intravenous-to-oral sequential therapy consisting of intravenous ceftriaxone (2g q24h) with or without clarithromycin (500mg q12h) followed by an oral antibiotic (a beta-lactam agent in the majority of patients). The primary study endpoint was the resolution of CAP; secondary endpoints included length of stay and overall mortality. CAP resolved in 72 of 79 (91.1%) patients in the levofloxacin group and in 34 of 37 (91.9%) patients in the intravenous-to-oral sequential therapy group (difference, −0.8%, 95%CI, −11.6-10.0). Median length of stay was 8 days (range, 2-74 days) in the levofloxacin group and 10 days (range, 3-29 days) in the intravenous-to-oral sequential therapy group (P=0.28). Day 30 mortality rates were 1.3% (1 of 79) and 8.1% (3 of 37), respectively (difference, −6.8%, 95%CI, −16.0-2.3). Full-course oral levofloxacin is as efficacious and as safe as standard intravenous-to-oral sequential antibiotic therapy for the treatment of hospitalized patients with CA